CDK4/6 inhibitors are used to treat both early-stage and advanced-stage hormone receptor-positive, HER2-negative breast cancer. The CDK4/6 inhibitors are: Ibrance (chemical name: palbociclib) Kisqali (chemical name: ribociclib) Verzenio (chemical name: abemaciclib) At the 2023 San Antonio Breast Cancer Symposium, Dr. Stephanie Graff moderated an educational session to help people and their doctors decide on treatments after a CDK4/6 inhibitor has stopped working. Listen to the podcast to hear Dr. Graff explain: how the oral SERD, Orserdu (chemical name: elacestrant), might be used how PARP inhibitors, such as Lynparza (chemical name: olaparib) or Talzenna (chemical name: talazoparib) might be used why using a CDK4/6 inhibitor after another CDK4/6 inhibitor probably won’t be used

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related